Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T15:00:10.540Z Has data issue: false hasContentIssue false
  • English
  • Français

The Multiple Facets of Treatment-Resistant Depression

Published online by Cambridge University Press:  07 November 2014

Daniel Souery  and
Karel Van der Auwera
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
CNS Spectrums , Volume 9 , Issue 11 , November 2004 , pp. 803 - 807
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Arbabzadeh-Bouchez, S, Tylee, A, Lepine, JP. A European perspective on depression in the community: the DEPRES Study. CNS Spectr. 2002;7:120–126.CrossRefGoogle ScholarPubMed
2. Tylee, A. Depression in Europe: experience from the DEPRES II survey. Depression Research in European Society. Eur Neuropsychopharmacol. 2000;10(suppl 4)S445–S448.CrossRefGoogle ScholarPubMed
3. Demyttenaere, K, Bruffaerts, R, Posada-Villa, J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291:2581–2590.Google ScholarPubMed
4. Thase, ME, Friedman, ES, Howland, RH. Venlafaxine and treatment resistant depression. Depress Anxiety. 2000;12(suppl 1):55–62.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
5. Thase, ME, Sloan, DM, Kornstein, SG. Remission as the critical outcome of depression treatment. Psychopharmacol Bull. 2002;36(4 suppl 3):12–25.Google ScholarPubMed
6. Berndt, ER, Bir, A, Busch, SH, Frank, RG, Normand, SL. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ. 2002;21:373–396.CrossRefGoogle ScholarPubMed
7. Thase, ME, Kupfer, DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol. 1996;64:646–659.CrossRefGoogle ScholarPubMed
8. Diagnostic and Statistical Manual of Mental Disorders. 4th ed-text rev. Washington, DC: American Psychiatric Association; 2001.Google Scholar
9. Sachs, GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am. 1996;19:215–236.CrossRefGoogle ScholarPubMed
10. Calabrese, JR, Kasper, S, Johnson, G, et al. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry. 2004;65:571–579.Google Scholar
11. Calabrese, JR. Depression mood stabilisation: novel concepts and clinical management. Eur Neuropsyhopharmacol. 2004;14(suppl 2):S100–S107.CrossRefGoogle ScholarPubMed
12. Goldsmith, DR, Wagstaff, AJ, Ibbotson, T, Perry, CM. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63:2029–2050.CrossRefGoogle ScholarPubMed
13. Calabrese, JR, Bowden, CL, McElroy, SL, et al. Spectrum activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999:156:1019–1023.CrossRefGoogle ScholarPubMed
14. Marangell, LB, Martinez, JM, Ketter, TA, et al. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disord. 2004:6:139–143.CrossRefGoogle ScholarPubMed
15. Calabrese, JR, Bowden, CL, Sachs, GS. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013–1024.CrossRefGoogle ScholarPubMed
16. Calabrese, JR, Suppes, T, Bowden, CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;61:841–850.CrossRefGoogle ScholarPubMed
17. Bowden, CL, Calabrese, JR, Yatham, LN, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392–400.CrossRefGoogle ScholarPubMed
18. Bowden, CL, Mitchell, P, Suppes, T. Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol. 1999;9(suppl 4): S113–S117.CrossRefGoogle ScholarPubMed
19. Calabrese, JR, Bowden, CL, Sachs, G, Ascher, JA, Monaghan, E, Rudd, GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88.CrossRefGoogle ScholarPubMed
20. Goodnick, PJ, Barrios, CA. Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother. 2001;3:667–680.CrossRefGoogle Scholar
21. Goodwin, FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry. 2003;64(suppl 5):18–24.Google ScholarPubMed
22. Vieta, E. Olanzapine in bipolar disorder. Expert Opin Pharmacother. 2004:5:1613–1619.CrossRefGoogle ScholarPubMed
23. Namojoshi, MA, Risser, R, Shi, L, Tohen, M, Breier, A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 2004;81:223–229.CrossRefGoogle Scholar
24. Sach, GS, Grossman, F, Ghaemi, SN, Okamoto, A, Bowden, CL. Combinatio n of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind placebo controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146–1154.CrossRefGoogle Scholar